Evidence map›Paper›PMID 30773117›Full record

ArticleLeukemia & lymphoma2019

HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.

Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, Shelley Orwick, Chaomei Liu, Janani Ravikrishnan, Jennifer Woyach, Alice Mims, William Plunkett, Vinay K Puduvalli and 3 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tzung-Huei LaiDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Shaneice MitchellDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Pei-Jung WuDivision of Neuro-oncology, Department of Neurosurgery, The Ohio State University , Columbus , OH , USA.
Shelley OrwickDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Chaomei LiuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Janani RavikrishnanDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Jennifer WoyachDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Alice MimsDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
William PlunkettDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Vinay K PuduvalliDivision of Neuro-oncology, Department of Neurosurgery, The Ohio State University , Columbus , OH , USA.
John C ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
Deepa SampathDivision of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
The Ohio State University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8M
Cancer and Leukemia Group B - The Ohio State UniversityU10CA077658 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 1998 to 2013
$6.0M
Targeting NAMPT in Acute Myeloid LeukemiaR01CA223165 · NCI · OHIO STATE UNIVERSITY · PI LAPALOMBELLA, ROSA, MIMS, ALICE SCOTT · 2018 to 2022
$2.3M
Patient Oriented Research Program in Neuro-oncologyK24CA160777 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PUDUVALLI, VINAY K · 2012 to 2015
$580k
NCI NIH HHS K24 CA160777NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA223165NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA180850
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsArabinonucleosidesBenzamidesCell Line, TumorCytosineDNA Breaks, Double-StrandedDNA RepairDrug Resistance, NeoplasmHSP90 Heat-Shock ProteinsHumansIsoindolesLeukemia, Myeloid, Acute(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanoneArabinonucleosidesBenzamidesCytosineHSP90 Heat-Shock ProteinsIsoindolessapacitabine

Identifiers

PMID30773117
PMCPMC7374815
OpenAlexW2918139254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.